Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Dow Climbs on Renewed Stimulus Hopes, Vaccine News

Published 12/01/2020, 12:55 PM
Updated 12/01/2020, 02:57 PM
© Reuters.
US500
-
DJI
-
MSFT
-
SPY
-
GOOGL
-
AMZN
-
PFE
-
KSS
-
IXIC
-
META
-
GOOG
-
MRNA
-
ZM
-
BNTX
-

By Yasin Ebrahim

Investing.com - The Dow rebounded Tuesday following a soft start to the week as renewed hopes on fiscal stimulus and positive vaccine news lifted investor sentiment and eased worries about Covid-19 infections across the U.S.

The Dow Jones Industrial Average climbed 0.91%, or 268 points. The S&P 500 was 1.34%, while the Nasdaq Composite rose 1.39%.

Pharmaceutical giants Pfizer and Moderna (NASDAQ:MRNA) moved closer to receiving EU approval for their respective Covid-19 vaccines after the European Medicines Agency said it could complete its assessment of both companies' vaccines by Dec. 29 and Jan. 12 respectively.

Pfizer (NYSE:PFE) rose 3% and its development partner BioNTech (NASDAQ:BNTX) fell 10%, while Moderna fell 12%.

The backdrop of progress on the vaccine front helped eased some investor fears that infections could continue to ramp in the weeks ahead as more people gather over the holidays.

U.S. coronavirus cases in America have doubled in a month to a record four million.

The impact of the rising Covid-19 cases appears to have triggered a sense of urgency among lawmakers to ramp-up efforts on a stimulus relief program that many argue is needed to support the economy until a widespread vaccine rollout.

House Speaker Nancy Pelosi and U.S. Treasury Secretary Steven Mnuchin are set to reignite talks over a new stimulus deal as lawmakers on Capitol Hill reportedly proposed a $908 billion coronavirus relief bill that includes aid for various parts of the economy including small businesses and unemployed Americans.

The positive news on vaccines prompted optimism from Federal Reserve Chairman Jerome Powell who touted upside risks in the medium-term for the economy, though continued to reiterate a long road to recovery. 

In the medium term, there is upside risk, though there in the near term, there are a lot of small businesses in danger of going out of business this winter," Powell said. "We do have a long way to go on recovery."

Value stocks – those linked with the performance of the economy, clawed back some of their losses from a day earlier, with financials among the biggest gainers, up nearly 2%.

Energy, however, lagged the move higher in value stocks after major producers delayed a decision on whether to ease production output from January until later this week.

In tech, Zoom Video Communications (NASDAQ:ZM) was among the biggest decliners of the session, down 15%, after the video conference software maker reported better-than-expected results and guidance, but warned of increased churn in the final quarter of the year that will slow revenue growth.

"Given the elevated expectations heading into the print, and the fear around what a post-COVID growth rate may look like for the company, we would expect near-term share weakness to persist," RBC said after cutting its price target on Zoom to $550 from $600.

Among the Fab 5 stocks, Facebook (NASDAQ:FB) surged nearly 4%, while Amazon.com (NASDAQ:AMZN), Alphabet (NASDAQ:GOOGL) and Microsoft (NASDAQ:MSFT) traded higher.

In other news, Kohl's (NYSE:KSS) jumped 14% after detailing plans to team up with Sephora to open more than 800 mini-shops inside its stores by 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.